# Idexx Laboratories Inc: financial statements, quarterly IDXX · Nasdaq · CIK 874716 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/idxx.md) · [Financials](/companies/idxx/financials.md) · [Filings](/companies/idxx/filings.md) · [Insiders](/companies/idxx/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/idxx/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [916](/filings/0000874716-24-000139.md) | [902 d](/filings/0000874716-26-000038.md) | [964](/filings/0000874716-25-000062.md) | [1,004](/filings/0000874716-25-000121.md) | [976](/filings/0000874716-25-000165.md) | [954 d](/filings/0000874716-26-000038.md) | [998](/filings/0000874716-26-000076.md) | [1,109](/filings/0000874716-26-000123.md) | [1,105](/filings/0000874716-25-000165.md) | [1,091 d](/filings/0000874716-26-000038.md) | [1,141](/filings/0000874716-26-000076.md) | [1,217](/filings/0000874716-26-000123.md) | | Cost of revenue | $m | [368](/filings/0000874716-24-000139.md) | [375 d](/filings/0000874716-24-000057.md) | [371](/filings/0000874716-25-000062.md) | [384](/filings/0000874716-24-000121.md) | [380](/filings/0000874716-24-000139.md) | [384 d](/filings/0000874716-26-000038.md) | [375](/filings/0000874716-25-000062.md) | [415](/filings/0000874716-26-000123.md) | [422](/filings/0000874716-25-000165.md) | [432 d](/filings/0000874716-26-000038.md) | [418](/filings/0000874716-26-000076.md) | [437](/filings/0000874716-26-000123.md) | | Gross profit | $m | [548](/filings/0000874716-24-000139.md) | [526 d](/filings/0000874716-26-000038.md) | [593](/filings/0000874716-25-000062.md) | [619](/filings/0000874716-25-000121.md) | [596](/filings/0000874716-25-000165.md) | [571 d](/filings/0000874716-26-000038.md) | [623](/filings/0000874716-26-000076.md) | [695](/filings/0000874716-26-000123.md) | [683](/filings/0000874716-25-000165.md) | [658 d](/filings/0000874716-26-000038.md) | [723](/filings/0000874716-26-000076.md) | [779](/filings/0000874716-26-000123.md) | | Research and development | $m | [48.0](/filings/0000874716-24-000139.md) | [51.8 d](/filings/0000874716-26-000038.md) | [52.6](/filings/0000874716-25-000062.md) | [55.5](/filings/0000874716-25-000121.md) | [54.0](/filings/0000874716-25-000165.md) | [57.7 d](/filings/0000874716-26-000038.md) | [59.1](/filings/0000874716-26-000076.md) | [61.9](/filings/0000874716-26-000123.md) | [63.4](/filings/0000874716-25-000165.md) | [66.8 d](/filings/0000874716-26-000038.md) | [65.8](/filings/0000874716-26-000076.md) | [65.4](/filings/0000874716-26-000123.md) | | Operating income | $m | [275](/filings/0000874716-24-000139.md) | [245 d](/filings/0000874716-26-000038.md) | [299](/filings/0000874716-25-000062.md) | [264](/filings/0000874716-25-000121.md) | [304](/filings/0000874716-25-000165.md) | [262 d](/filings/0000874716-26-000038.md) | [317](/filings/0000874716-26-000076.md) | [373](/filings/0000874716-26-000123.md) | [355](/filings/0000874716-25-000165.md) | [316 d](/filings/0000874716-26-000038.md) | [363](/filings/0000874716-26-000076.md) | [426](/filings/0000874716-26-000123.md) | | Interest expense | $m | [8.6](/filings/0000874716-23-000128.md) | [9.3 d](/filings/0000874716-24-000057.md) | [7.9](/filings/0000874716-24-000083.md) | [8.1](/filings/0000874716-25-000121.md) | [7.7](/filings/0000874716-25-000165.md) | [7.5 d](/filings/0000874716-26-000038.md) | [7.7](/filings/0000874716-26-000076.md) | [11.3](/filings/0000874716-26-000123.md) | [10.7](/filings/0000874716-25-000165.md) | [9.2 d](/filings/0000874716-26-000038.md) | [7.7](/filings/0000874716-26-000076.md) | [10.2](/filings/0000874716-26-000123.md) | | Income tax | $m | [55.7](/filings/0000874716-24-000139.md) | [45.1 d](/filings/0000874716-26-000038.md) | [59.9](/filings/0000874716-25-000062.md) | [55.8](/filings/0000874716-25-000121.md) | [66.1](/filings/0000874716-25-000165.md) | [40.2 d](/filings/0000874716-26-000038.md) | [67.4](/filings/0000874716-26-000076.md) | [68.4](/filings/0000874716-26-000123.md) | [70.2](/filings/0000874716-25-000165.md) | [58.8 d](/filings/0000874716-26-000038.md) | [77.0](/filings/0000874716-26-000076.md) | [78.8](/filings/0000874716-26-000123.md) | | Net income | $m | [212](/filings/0000874716-24-000139.md) | [195 d](/filings/0000874716-26-000038.md) | [236](/filings/0000874716-25-000165.md) | [203](/filings/0000874716-25-000165.md) | [233](/filings/0000874716-25-000165.md) | [216 d](/filings/0000874716-26-000038.md) | [243](/filings/0000874716-26-000123.md) | [294](/filings/0000874716-26-000123.md) | [275](/filings/0000874716-25-000165.md) | [248 d](/filings/0000874716-26-000038.md) | [278](/filings/0000874716-26-000123.md) | [338](/filings/0000874716-26-000123.md) | | Diluted EPS | $ per share | [2.53](/filings/0000874716-24-000139.md) | not reported | [2.81](/filings/0000874716-25-000062.md) | [2.44](/filings/0000874716-25-000121.md) | [2.80](/filings/0000874716-25-000165.md) | not reported | [2.96](/filings/0000874716-26-000076.md) | [3.63](/filings/0000874716-26-000123.md) | [3.40](/filings/0000874716-25-000165.md) | not reported | [3.47](/filings/0000874716-26-000076.md) | [4.27](/filings/0000874716-26-000123.md) | | Basic EPS | $ per share | [2.55](/filings/0000874716-24-000139.md) | not reported | [2.84](/filings/0000874716-25-000062.md) | [2.46](/filings/0000874716-25-000121.md) | [2.83](/filings/0000874716-25-000165.md) | not reported | [2.98](/filings/0000874716-26-000076.md) | [3.66](/filings/0000874716-26-000123.md) | [3.43](/filings/0000874716-25-000165.md) | not reported | [3.50](/filings/0000874716-26-000076.md) | [4.29](/filings/0000874716-26-000123.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue, us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [332](/filings/0000874716-23-000128.md) | [454](/filings/0000874716-25-000037.md) | [397](/filings/0000874716-24-000083.md) | [402](/filings/0000874716-24-000121.md) | [309](/filings/0000874716-24-000139.md) | [288](/filings/0000874716-26-000038.md) | [164](/filings/0000874716-25-000062.md) | [165](/filings/0000874716-25-000121.md) | [208](/filings/0000874716-25-000165.md) | [180](/filings/0000874716-26-000123.md) | [201](/filings/0000874716-26-000076.md) | [197](/filings/0000874716-26-000123.md) | | Current assets | $m | [1,384](/filings/0000874716-23-000128.md) | [1,495](/filings/0000874716-25-000037.md) | [1,502](/filings/0000874716-24-000083.md) | [1,529](/filings/0000874716-24-000121.md) | [1,434](/filings/0000874716-24-000139.md) | [1,400](/filings/0000874716-26-000038.md) | [1,318](/filings/0000874716-25-000062.md) | [1,362](/filings/0000874716-25-000121.md) | [1,477](/filings/0000874716-25-000165.md) | [1,414](/filings/0000874716-26-000123.md) | [1,454](/filings/0000874716-26-000076.md) | [1,509](/filings/0000874716-26-000123.md) | | Total assets | $m | [3,086](/filings/0000874716-23-000128.md) | [3,260](/filings/0000874716-25-000037.md) | [3,354](/filings/0000874716-24-000083.md) | [3,415](/filings/0000874716-24-000121.md) | [3,351](/filings/0000874716-24-000139.md) | [3,293](/filings/0000874716-26-000038.md) | [3,214](/filings/0000874716-25-000062.md) | [3,331](/filings/0000874716-25-000121.md) | [3,387](/filings/0000874716-25-000165.md) | [3,351](/filings/0000874716-26-000123.md) | [3,385](/filings/0000874716-26-000076.md) | [3,442](/filings/0000874716-26-000123.md) | | Current liabilities | $m | [970](/filings/0000874716-23-000128.md) | [952](/filings/0000874716-25-000037.md) | [957](/filings/0000874716-24-000083.md) | [1,117](/filings/0000874716-24-000121.md) | [1,009](/filings/0000874716-24-000139.md) | [1,068](/filings/0000874716-26-000038.md) | [1,136](/filings/0000874716-25-000062.md) | [1,224](/filings/0000874716-25-000121.md) | [1,252](/filings/0000874716-25-000165.md) | [1,149](/filings/0000874716-26-000123.md) | [1,300](/filings/0000874716-26-000076.md) | [1,288](/filings/0000874716-26-000123.md) | | Total liabilities | $m | [1,789](/filings/0000874716-23-000128.md) | [1,775](/filings/0000874716-25-000037.md) | [1,785](/filings/0000874716-24-000083.md) | [1,835](/filings/0000874716-24-000121.md) | [1,733](/filings/0000874716-24-000139.md) | [1,698](/filings/0000874716-26-000038.md) | [1,766](/filings/0000874716-25-000062.md) | [1,872](/filings/0000874716-25-000121.md) | [1,826](/filings/0000874716-25-000165.md) | [1,745](/filings/0000874716-26-000123.md) | [1,829](/filings/0000874716-26-000076.md) | [1,830](/filings/0000874716-26-000123.md) | | Long-term debt | $m | [619](/filings/0000874716-23-000128.md) | [623](/filings/0000874716-25-000037.md) | [621](/filings/0000874716-24-000083.md) | [525](/filings/0000874716-24-000121.md) | [525](/filings/0000874716-24-000139.md) | [450](/filings/0000874716-26-000038.md) | [450](/filings/0000874716-25-000062.md) | [450](/filings/0000874716-25-000121.md) | [375](/filings/0000874716-25-000165.md) | [375](/filings/0000874716-26-000123.md) | [300](/filings/0000874716-26-000076.md) | [300](/filings/0000874716-26-000123.md) | | Current portion of debt | $m | [150](/filings/0000874716-23-000128.md) | [75.0](/filings/0000874716-25-000037.md) | [75.0](/filings/0000874716-24-000083.md) | [170](/filings/0000874716-24-000121.md) | [99.1](/filings/0000874716-24-000139.md) | [168](/filings/0000874716-26-000038.md) | [171](/filings/0000874716-25-000062.md) | [75.0](/filings/0000874716-25-000121.md) | [150](/filings/0000874716-25-000165.md) | [75.0](/filings/0000874716-26-000123.md) | [150](/filings/0000874716-26-000076.md) | [150](/filings/0000874716-26-000123.md) | | Shareholders' equity | $m | [1,297](/filings/0000874716-24-000139.md) | [1,485](/filings/0000874716-26-000038.md) | [1,569](/filings/0000874716-25-000165.md) | [1,580](/filings/0000874716-25-000165.md) | [1,618](/filings/0000874716-25-000165.md) | [1,595](/filings/0000874716-26-000123.md) | [1,448](/filings/0000874716-26-000123.md) | [1,459](/filings/0000874716-26-000123.md) | [1,561](/filings/0000874716-25-000165.md) | [1,605](/filings/0000874716-26-000123.md) | [1,556](/filings/0000874716-26-000123.md) | [1,613](/filings/0000874716-26-000123.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [272 d](/filings/0000874716-24-000139.md) | [250 d](/filings/0000874716-26-000038.md) | [199](/filings/0000874716-25-000062.md) | [248 d](/filings/0000874716-25-000121.md) | [220 d](/filings/0000874716-25-000165.md) | [262 d](/filings/0000874716-26-000038.md) | [238](/filings/0000874716-26-000076.md) | [186 d](/filings/0000874716-26-000123.md) | [402 d](/filings/0000874716-25-000165.md) | [356 d](/filings/0000874716-26-000038.md) | [266](/filings/0000874716-26-000076.md) | [347 d](/filings/0000874716-26-000123.md) | | Capital expenditure | $m | [34.1 d](/filings/0000874716-24-000139.md) | [32.6 d](/filings/0000874716-26-000038.md) | [30.3](/filings/0000874716-25-000062.md) | [33.3 d](/filings/0000874716-25-000121.md) | [28.1 d](/filings/0000874716-25-000165.md) | [29.3 d](/filings/0000874716-26-000038.md) | [30.0](/filings/0000874716-26-000076.md) | [34.1 d](/filings/0000874716-26-000123.md) | [31.1 d](/filings/0000874716-25-000165.md) | [29.4 d](/filings/0000874716-26-000038.md) | [32.0](/filings/0000874716-26-000076.md) | [24.6 d](/filings/0000874716-26-000123.md) | | Share repurchases | $m | [35.1 d](/filings/0000874716-24-000139.md) | [36.9 d](/filings/0000874716-26-000038.md) | [155](/filings/0000874716-25-000062.md) | [216 d](/filings/0000874716-25-000121.md) | [221 d](/filings/0000874716-25-000165.md) | [246 d](/filings/0000874716-26-000038.md) | [401](/filings/0000874716-26-000076.md) | [338 d](/filings/0000874716-26-000123.md) | [240 d](/filings/0000874716-25-000165.md) | [238 d](/filings/0000874716-26-000038.md) | [351](/filings/0000874716-26-000076.md) | [347 d](/filings/0000874716-26-000123.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [84.1](/filings/0000874716-23-000128.md) | [84.0](/filings/0000874716-24-000083.md) | [84.0](/filings/0000874716-24-000121.md) | [84.0](/filings/0000874716-24-000139.md) | [84.0](/filings/0000874716-25-000062.md) | [83.4](/filings/0000874716-25-000121.md) | [83.1](/filings/0000874716-25-000165.md) | [81.9](/filings/0000874716-26-000076.md) | [81.0](/filings/0000874716-26-000123.md) | [80.7](/filings/0000874716-25-000165.md) | [80.2](/filings/0000874716-26-000076.md) | [79.3](/filings/0000874716-26-000123.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 78,781,116 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0000874716-26-000123.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.